(MedPage Today) — SEATTLE — The monoclonal antibody romosozumab (Evenity) increased bone mineral density (BMD) in premenopausal women with idiopathic osteoporosis, according to a small, phase II open-label study.
Among the 29 women enrolled…
Source link : https://www.medpagetoday.com/meetingcoverage/asbmr/117356
Author :
Publish date : 2025-09-08 15:04:00
Copyright for syndicated content belongs to the linked Source.
